AzTrials
AzTrials

Type 2 DiabetesNCT05001815

CSII Versus MDI in Pregnant Women With Type 2 Diabetes

A study testing Continuous subcutaneous insulin infusion (CSII) and Multiple daily insulin injection (MDI) in people with Type 2 Diabetes and Pregnancy in Diabetic, run by Peking University Third Hospital at 1 site in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The primary objective of the study is to determine if continuous subcutaneous insulin infusion (CSII) can improve glycemic control in women with type 2 diabetes (T2D) who are pregnant. Read more about this study

Who is it for?
Ages 18 to 40 years, women only
Conditions the study is for
Type 2 Diabetes, Pregnancy in Diabetic
What is being tested?
Continuous subcutaneous insulin infusion (CSII) and Multiple daily insulin injection (MDI)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
80 participants
Where
1 siteChina
Study dates
15 Dec 2021to 1 Oct 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 40 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • Women aged 18 to 40 years old
  • Patients with confirmed history of T2D or patients who are newly diagnosed with T2D by oral glucose tolerance test (OGTT) during pregnancy (diagnostic criteria refer to ADA 2020 guideline for T2D).
  • Women with singleton pregnancy at 4 to 20 weeks of gestation, whose blood glucose fails to achieved glucose target after adequate lifestyle intervention with or without the prescription of basal insulin (i.e. fasting blood glucose above 5.3 mmol/L, or one hour postprandial blood glucose above 7.8 mmol/L, or two hour postprandial blood glucose above 6.7 mmol/L), and need to start intensive insulin therapy (MDI or insulin pump) according to the evaluation of endocrinologists.
  • Patients who are willing be followed up by the Third Hospital of Peking University in the whole process of pregnancy until 6 weeks of postpartum, and promise that they will provide the results of relative prenatal examinations and perinatal medical records if they are transferred to another hospital for special reasons.
  • Patients who can pass the compliance test and agree to conduct self-monitoring of blood glucose (SMBG) at least 7 times a day during pregnancy.
  • Patients who volunteer to participate the trial and agree to sign informed consent.

Who cannot join

  • Patients with T1D, special type of diabetes and gestational diabetes.
  • Patients who have received intensive insulin therapy (MDI or insulin pump) or premixed fixed doses of insulin before enrollment in this trial.
  • Patients who refuse to use insulin pump or CGM devices.
  • Patients who are not recommended by obstetrician to continue their pregnancy due to comorbidity and high risk of pregnancy. The comorbidities include but not limited to the following diseases: proliferative retinopathy, chronic kidney disease (eGFR less than 60 ml /min/1.73 with or without heavy proteinuria), known coronary heart disease and cerebrovascular disease, autoimmune disease, other diseases requiring exogenous glucocorticoid or immunosuppressive therapy.
  • Patients who received inpatient psychiatric treatment within 6 months before enrollment or still using psychiatric drugs.
  • Participated in other intervention studies.

Trial locations and contacts

1 site in 1 country.

Haining Wang, MD and Ph.D contact

+86-18211087263

hainingmail@bjmu.edu.cn

China1 site
  • Peking University Third Hospital

    Beijing, Beijing Municipality, 100191

    Wang Haining, PhD

Other trials in China

About this study

Official title: Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injection in Pregnant Women With Type 2 Diabetes: A Single-center Open Label Randomized Controlled Trial

The primary objective of the study is to determine if continuous subcutaneous insulin infusion (CSII) can improve glycemic control in women with type 2 diabetes (T2D) who are pregnant.

Read the detailed description

In women with diabetes, hyperglycemia is associated with increased rates of maternal and fetal adverse outcomes. Mothers are at increased risk of preeclampsia, deterioration of proteinuria and caesarean sections. Infants of mothers with diabetes have increased rates of congenital anomalies, premature delivery, macrosomia, stillbirth and NICU admissions, as well as increased risks of shoulder dystocia, birth injury, hypoglycemia, hyperbilirubinemia, respiratory distress syndrome, asphyxia and death in the neonatal period. Several studies have shown that pregnancy outcomes can be improved along with better glycemic control. Theoretically CSII could achieve better glycemic control due to its flexibility in adjusting both basal rate and bolus insulin infusion. Several randomized controlled studies have compared the ability of CSII with multiple daily injection (MDI) in glycemic control and improvement of pregnancy outcomes in patients with type 1 diabetes (T1D). However, there is a lack of similar studies in women with T2D. We hypothesize that CSII will assist women with T2D achieve better glycemic control during pregnancy compared to MDI users.

Being tested
Continuous subcutaneous insulin infusion (CSII), Multiple daily insulin injection (MDI)
Keywords
type 2 diabetes, pregnancy, continuous subcutaneous insulin infusion, multiple daily injection
Medical subject headings
Diabetes Mellitus, Type 2, Pregnancy in Diabetics

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Continuous subcutaneous insulin infusion (CSII)Device

    The CSII device used in this study has access to mobile phone, however, without CGM enhanced function

  • Multiple daily insulin injection (MDI)Device

    Patients with indication will receive MDI treatment with at least one basal insulin injection plus 2 to 3 prandial insulin injection.

Study groups in NCT05001815
Study groupRoleWhat they receive
Continuous subcutaneous insulin infusion (CSII)ExperimentalPatients with indications will receive continuous subcutaneous insulin infusion (CSII) treatment achieved by patch insulin pump devices.
Receives: Device: Continuous subcutaneous insulin infusion (CSII)
Multiple daily insulin injection (MDI)Active comparatorPatients with indications will receive traditional multiple daily insulin injection (MDI) treatment.
Receives: Device: Multiple daily insulin injection (MDI)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Time in range (TIR) at 24 weeks of gestation

    Glycemic control as measured by time in range (TIR) acquired from retrospective continuous glucose monitoring devices (r-CGM) at 24 weeks of gestation among women with type 2 diabetes mellitus.

    Measured: 24 weeks of gestation

  2. Time in range (TIR) at 28 weeks of gestation

    Glycemic control as measured by time in range (TIR) acquired from retrospective continuous glucose monitoring devices (r-CGM) at 28 weeks of gestation among women with type 2 diabetes mellitus.

    Measured: 28 weeks of gestation

  3. Time in range (TIR) at 34 weeks of gestation

    Glycemic control as measured by time in range (TIR) acquired from retrospective continuous glucose monitoring devices (r-CGM) at 34 weeks of gestation among women with type 2 diabetes mellitus.

    Measured: 34 weeks of gestation

Secondary outcomes (23)
  1. Glycosylated hemoglobin (HbA1c) and glycosylated serum albumin

    Glycosylated hemoglobin (HbA1c) and glycosylated serum albumin in meta-late phase of pregnancy.

    Measured: 24, 28, 34 weeks of gestation and 6 weeks of postpartum

  2. TIR calculated by patients' SMBG data

    TIR calculated by patients' SMBG data at 4 weeks after randomization, and at 24, 28, 34 and 38 weeks of gestation.

    Measured: At 4 weeks after randomization, and at 24, 28, 34 and 38 weeks of gestation

  3. TAR and TBR

    Time above range (TAR) and time below range (TBR) calculated by CGM data at 24, 28 and 34 weeks of gestation.

    Measured: At 24, 28 and 34 weeks of gestation

  4. Blood glucose fluctuation index

    Mean amplitude of glucose excursion (MAGE), coefficient of variation (CV) and standard deviation (SD) calculated by CGM data recorded at 24, 28 and 34 weeks of gestation.

    Measured: At 24, 28 and 34 weeks of gestation

  5. The AUC of blood glucose within 24 hours before delivery

    The area under curve (AUC) of peripheral blood glucose within 24 hours before delivery: (a) >7.8 mmol/l or 140 mg/dl (b)>6.7 mmol/l or 120 mg/dl (c) <3.5 mmol/L or <63 mg/dl (d) <2.8 mmol/L or <50 mg/dl.

    Measured: Within 24 hours before delivery

  6. Hypoglycemic events

    (a)Episodes of severe hypoglycemia requiring assistance. (b)Episodes of mild-moderate episodes of hypoglycemia < 3.5mmol/L (mild) and < 2.8 mmol/L (moderate) from patients' SMBG data or from CGM data defined as AUC <3.5 mmol/L or AUC less than or equal to 2.8 mmol/L for 20 minutes duration. (c) Nocturnal hypoglycemia defined as glucose <3.5 (mild) and <2.8 (moderate) by SMBG or CGM between the hours of 23.00-07.00.

    Measured: From randomization, up to 42 weeks of gestation

  7. Insulin requirements

    The total daily insulin dosage at randomization, 4 weeks after randomization, and 24, 28, 34 weeks of gestation as well as 6 weeks of postpartum.

    Measured: 4 weeks after randomization, 24, 28, 34 weeks of gestation and 6 weeks of postpartum.

  8. Hypertension during pregnancy

    Hypertension during pregnancy (up to 42 weeks of gestation): Incidence of worsening of chronic hypertension, gestational hypertension, preeclampsia.

    Measured: From randomization, up to 42 weeks of gestation

  9. Caesarean sections at delivery

    Incidence of caesarean section (primary and total)

    Measured: At delivery

  10. Gestational weight gain

    Gestational weight gain: Absolute and relative weight gain at 24, 28, 34 weeks of gestation and 6 weeks of postpartum comparing to baseline (4-8 weeks of gestation at the time of enrollment)

    Measured: 24, 28, 34 weeks of gestation and 6 weeks of postpartum

  11. Maternal hospital stay

    Length of hospital stay including admission for delivery and for other obstetric situations during pregnancy.

    Measured: From admission to discharge from hospital due to delivery

  12. Infant birthweight

    Infant birthweight (at birth): Infant birthweight>90th centile using customized growth curves; infant birthweight<10th centile using customized growth curves; infant birthweight≥4000g or ≤2500g.

    Measured: At delivery

  13. Pregnancy loss

    Including miscarriage, stillbirth and neonatal death (≤28 days of life).

    Measured: From randomization, up to 28 days after delivery

  14. Infant Outcomes (Gestational week of delivery)

    Infant Outcomes (at birth): The incidence of preterm delivery (<37 weeks and early preterm <34 weeks) and post-term delivery (>42 weeks).

    Measured: At birth

  15. Infant Outcomes (Apgar score)

    Infant Outcomes (at birth): Apgar score

    Measured: At birth

  16. Infant Outcomes (Up to first 7 days of infants' life)

    The incidence of birth injury, shoulder dystocia, neonatal hypoglycemia with intravenous dextrose.

    Measured: Up to first 7 days of infants' life

  17. Infant Outcomes (Up to f first 7 days of life)

    Incidence of hyperbilirubinemia, respiratory Distress Syndrome (RDS), NICU admission > 24 hours.

    Measured: Up to first 7 days of infants' life

  18. The composite endpoint of infants

    The combined adverse outcomes of infants including miscarriage, stillbirth and neonatal death; Neonatal birth injury, shoulder dystocia, neonatal hypoglycemia (requiring intravenous glucose infusion), neonatal jaundice, neonatal respiratory distress syndrome (RDS) and more than 24 hours of treatment in NICU.

    Measured: Up to first 7 days of infants' life

  19. Questionnaires (WHO-5 physical and mental health index)

    The score of World health organization (WHO)-5 physical and mental health index acquired from patients.

    The WHO-5 scale (1998 version) was used to measure the patient's quality of life. The scale contains 5 items which initial points is 0-25. The initial points are multiplied by 4 to obtain the percentage points, ranging from 0 to 100,which are used to monitor possible changes in physical and mental health. 0 represents the worst possible quality of life, 100 represents the best possible quality of life, and a difference of 10% indicates significant changes.

    Measured: At randomization, 34 weeks of gestation and 6 weeks of postpartum

  20. Questionnaires (Self-manage behavior scale)

    The score of Self-manage behavior scale acquired from patients. Diabetes self-care behaviors includes a range of activities (e.g., eating diabetic food, exercising, glucose monitoring and taking medicine), which were evaluated by the Summary of Diabetes Self-Care Activities (SDSCA). SDSCA, compiled by Toobert in 2000, is an 8-likert scale containing 11 items belongs to 6 dimensions, could estimate general diet, special diet, physical activity, glucose monitoring, foot care and medicine compliance of patients with T2DM. The total scores range from 0 to 77, higher score means better diabetes self- care behaviors.

    Measured: At randomization, 34 weeks of gestation and 6 weeks of postpartum

  21. Questionnaires (Self-efficacy scale for diabetes mellitus)

    The score of self-efficacy scale for diabetes mellitus acquired from patients. Self-Efficacy for Diabetes (SED), a 5-Likert scale including 9 items, is used to measure patients' self-efficacy. The average score is 1-5 points, and the higher the average score, the higher the self-efficacy level of participants. The effectiveness and internal consistency of the Chinese version of SED are reliable, and the load factors of each factor are between 0.579-0.922.

    Measured: At randomization, 34 weeks of gestation and 6 weeks of postpartum

  22. Questionnaires (Self-rated Anxiety Scale, SAS)

    The score of Self-rated Anxiety Scale (SAS) acquired from patients. Self-Rating Anxiety Scale (SAS) is used to measure the degree of anxiety in patients. There are 20 items in total. The scores are divided into 4 levels, including 5 (items 5, 9, 13, 17, 19) reverse scoring items and 15 positive scoring items. Add the scores of the 20 items to get the rough score, then multiply it by 1.25 and take the integer part to get the standard score. The higher the standard score, the more serious the degree of anxiety.

    Measured: At randomization, 34 weeks of gestation and 6 weeks of postpartum

  23. Questionnaires (Self-rated Depression Scale, SDS)

    The score of Self-rated Depression Scale (SDS) acquired from patients. The Self-Rating Depression Scale (SDS) is used to measure the degree of depression in patients. There are 20 items in total, including 10 (items 2, 5, 6, 11, 12, 14, 16, 17, 18, and 20) reverse scoring items, and 15 positive scoring items. The depression severity index can be calculated by the cumulative score of each item divided by 80, which could reflect the degree of depression. The index range is 0.25-1.0, and the higher the index, the more severe the degree of depression.

    Measured: At randomization, 34 weeks of gestation and 6 weeks of postpartum

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Aug 2021
  2. Study start15 Dec 2021 (estimated)
  3. Primary completion1 Aug 2023 (estimated)
  4. Study completion1 Oct 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
80 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05001815
Sponsor's protocol ID
2021NFM001
Status last verified
Jul 2021
First submitted
26 Jul 2021
Last updated
30 Nov 2021
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Other researchers can contact the research group for IPD only for academic research, after the ethics committee re-evaluation and determination that the data transmission did not cause privacy disclosure to patients.

Questions about this trial

What is this clinical trial studying?

A study testing Continuous subcutaneous insulin infusion (CSII) and Multiple daily insulin injection (MDI) in people with Type 2 Diabetes and Pregnancy in Diabetic, run by Peking University Third Hospital at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 30 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Haining Wang, MD and Ph.D (+86-18211087263, hainingmail@bjmu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Time in range (TIR) at 24 weeks of gestation (time frame: 24 weeks of gestation). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Nov 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in